Thymosin-α1 Clinical Trial Investigates Safety and Efficacy for Recurrent Implantation Failure

Approximately 10-15% of couples experience infertility, with a significant subset facing recurrent implantation failure (RIF), defined as the inability to achieve pregnancy after multiple embryo transfers. Current standard-of-care often falls short for unexplained RIF, suggesting underlying immunological factors may play a crucial role. Early pregnancy success relies on a delicate maternal immune tolerance, often mediated by Treg cell expansion, influenced by progesterone and paternal antigens. Thymosin-α1 (Tα1) is an immunomodulatory peptide known to enhance T-cell function and modulate immune responses, making it a candidate for addressing immune dysregulation in RIF.

This clinical trial is designed to assess the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive therapy in women diagnosed with unexplained recurrent implantation failure (RIF). Participants are women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles. The study aims to evaluate whether the addition of Tα1 can improve pregnancy outcomes by modulating the immune environment. Specific details regarding the dosage, route of administration, frequency, duration of treatment, and the total number of participants (n) were not provided in the abstract. The primary endpoints are focused on the safety profile and efficacy in achieving successful implantation and pregnancy.